Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region

Diabetologia

Volumn 50, Issue 11, 2007, Pages 2289-2297

 

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Asia Pacific; Cardiovascular diseases; Cardiovascular risk; Cholesterol; Coronary heart disease; Diabetes mellitus; Lipids; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; ETHNICITY; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

EID: 34848908755     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0801-2     Document Type: Article

References (27)

1. Asia Pacific Cohort Studies Collaboration (2003) The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia Pacific region. Diabetes Care 26:360-366
2. Adlerberth AM, Rosengren A, Wilhelmsen L (1998) Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 21:539-545
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
4. Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8-13
5. Pyorala K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524
6. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184
7. Asia Pacific Cohort Studies Collaboration (1999) Determinants of cardiovascular disease in the Asia Pacific Region: protocol for a collaborative overview of cohort studies. Cardiovasc Dis Prev 2:281-289
8. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
9. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
10. Easton DF, Peto J, Babiker AG (1991) Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 10:1025-1035
11. Balkau B, Eschwege E, Papoz L et al (1993) Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 307:295-299
12. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM (2005) Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 28:1916-1921
13. Asia Pacific Cohort Studies Collaboration (2003) Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 32:563-572
14. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559
15. Critchley J, Liu J, Zhao D, Wei W, Capewell S (2004) Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 110:1236-1244
16. Zhang LF, Yang J, Hong Z et al (2003) Proportion of different subtypes of stroke in China. Stroke 34:2091-2096
17. Suh I (2001) Cardiovascular mortality in Korea: a country experiencing epidemiologic transition. Acta Cardiol 56:75-81
18. Kitamura A, Iso H, Iida M et al (2002) Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 112:104-109
19. Jiang B, Wang WZ, Chen H et al (2006) Incidence and trends of stroke and its subtypes in China: results from three large cities. Stroke 37:63-68
20. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
21. The J-LIT Study Group (2006) Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 191:440-446
22. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
23. Sever PS, Dahlof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
24. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620
25. Costa J, Borges M, David C, Carneiro AV (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332:1115-1124
26. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
27. Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861